Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
Katsuhiro ItoTakashi KobayashiTakahiro KojimaKensuke HikamiTakeshi YamadaKosuke OgawaKenji NakamuraNaoto SassaAkira YokomizoTakashige AbeKazunari TsuchihashiShuichi TataranoJunichi InokuchiRyotaro TomidaMaki FujiwaraAtsushi TakahashiKazumasa MatsumotoKosuke ShimizuHiromasa ArakiRyoma KurahashiYu OsakiYu TashiroMasayuki UegakiOsamu OgawaHiroshi KitamuraHiroyuki NishiyamaPublished in: Cancer medicine (2021)
PS ≥2 portended worse ORR and OS than PS ≤1 despite a comparable safety profile. Among the patients with impaired PS, patients with NLR <3.5 and no liver metastasis may most greatly benefit from pembrolizumab therapy.